ACE and Hypertension: Such promising results allowed the US Joint National Committee on hypertension in their seventh report (JNC-7) and the European Society of Hypertension (ESH-ESC) in the 2003 guidelines to integrate this class of agents in the management of hypertension and to propose AIIRAs as an alternative treatment to ACE-inhibitors for most of the above-mentioned high-risk conditions [8,9].